Abstract
Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with a potent neuronal differentiating activity. Recently, PEDF is found to be a highly effective inhibitor of pathological angiogenesis in both cell culture and animal models. Further, it has also been shown to have neuroprotective, anti-oxidative and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of cardiometabolic disorders, neurodegenerative disease and cancers. However, as far as we know, there are few comprehensive reviews to deal with the involvement of PEDF in hepatic disease. This article summarizes the pathophysiological role of PEDF for various liver diseases such as hepatic insulin resistance, alcoholic and nonalcoholic liver disease, and hepatocellular carcinoma, and its potential therapeutic implication in these devastating disorders.
Keywords: hepatic insulin resistance, oxidative stress, hepatocellular carcinoma, PEDF
Current Medicinal Chemistry
Title: Pathophysiological Role of Pigment Epithelium-Derived Factor (PEDF) in Hepatic Disorders
Volume: 17 Issue: 19
Author(s): S.-I. Yamagishi, T. Matsui, T. Kawaguchi and M. Sata
Affiliation:
Keywords: hepatic insulin resistance, oxidative stress, hepatocellular carcinoma, PEDF
Abstract: Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with a potent neuronal differentiating activity. Recently, PEDF is found to be a highly effective inhibitor of pathological angiogenesis in both cell culture and animal models. Further, it has also been shown to have neuroprotective, anti-oxidative and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of cardiometabolic disorders, neurodegenerative disease and cancers. However, as far as we know, there are few comprehensive reviews to deal with the involvement of PEDF in hepatic disease. This article summarizes the pathophysiological role of PEDF for various liver diseases such as hepatic insulin resistance, alcoholic and nonalcoholic liver disease, and hepatocellular carcinoma, and its potential therapeutic implication in these devastating disorders.
Export Options
About this article
Cite this article as:
Yamagishi S.-I., Matsui T., Kawaguchi T. and Sata M., Pathophysiological Role of Pigment Epithelium-Derived Factor (PEDF) in Hepatic Disorders, Current Medicinal Chemistry 2010; 17 (19) . https://dx.doi.org/10.2174/092986710791233670
DOI https://dx.doi.org/10.2174/092986710791233670 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of the Surfactant and Liquid Lipid Type in the Physico-chemical Characteristics of Beeswax-based Nanostructured Lipid Carrier (NLC) of Metformin
Pharmaceutical Nanotechnology Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design Aldosterone and Resistant Hypertension
Current Hypertension Reviews New Effects of Prebiotics, Probiotics, and Symbiotics
Current Clinical Pharmacology Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Insights into the Regulation of Renal Hemodynamic Function in Diabetic Mellitus
Current Diabetes Reviews Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets Diabetes and its Complications - Contemporary Treatment and Potential Side Effects of Drugs to Treat Diabetes
Current Drug Safety Lessons from the REACH Registry in Europe
Current Vascular Pharmacology MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Podocytes as a Target of Prorenin in Diabetes
Current Diabetes Reviews Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Current Pharmaceutical Design Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review
Current Stem Cell Research & Therapy Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry Vascular Calcification and not Arrhythmia in Idiopathic Atrial Fibrillation Associates with Sex Differences in Diabetic Microvascular Injury miRNA Profiles
MicroRNA Mitochondria-Targeted Drugs
Current Molecular Pharmacology